IL-6受体及其受体抗体在Graves眼病中的作用研究进展  

Update of interleukin-6 receptor and its antibody′s role in Graves′orbitopathy

作　　者：谭婕 徐书杭[1] Tan Jie;Xu Shuhang(Department of Endocrinology,Affiliated Hospital of Integrated Traditional Chinese and Western Medicine,Nanjing University of Chinese Medicine,Nanjing 210028,China)

机构地区：[1]南京中医药大学附属中西医结合医院内分泌科,南京210028

出　　处：《国际内分泌代谢杂志》2023年第5期380-383,共4页International Journal of Endocrinology and Metabolism

基　　金：2020年江苏省重点研发计划(BE2020726);江苏省卫生健康委医学科研项目(面上项目,M2020102);中华国际医学交流基金会甲状腺中青年医生研究项目(BQE-JZX-202115)。

摘　　要：Graves眼病(Graves′orbitopathy,GO)是Graves病(Graves′disease,GD)的主要甲状腺外表现。中度至重度GO是治疗的主要挑战,因其通常对现有的药物治疗反应不完全。糖皮质激素是中重度活动性GO的一线治疗方案,但有不少GO患者存在糖皮质激素治疗抵抗。研究已表明,白细胞介素(IL)-6受体参与了GO的发展。作为一种直接针对IL-6的重组人源化单克隆抗体,托珠单抗在临床研究中被证实对中到重度糖皮质激素抵抗的GO患者确有疗效,这表明靶向阻断IL-6受体的药物未来可能在GO治疗中占有一席之地。Graves′orbitopathy(GO)is the main extrathyroidal manifestation of Graves′disease(GD).GO is a major therapeutic challenge in its moderate-to-severe forms,often incompletely responsive to available medical treatments.Glucocorticoids are the first-line treatment for moderate to severe active Graves′orbitopathy(GO),but a certain amount of GO patients are still refractory to glucocorticoids treatment.Previous research have found that IL-6R participates in the development of GO.As a recombinant humanized monoclonal antibody directed against the IL-6 receptor,TCZ has shown its efficacy in moderate to severe glucocorticoid resistant GO patients.Therefore,drugs targeting IL-6R may claim its place in GO treatment someday.

关 键 词：GRAVES眼病 白细胞介素-6 白细胞介素-6受体 托珠单抗 

分 类 号：R581[医药卫生—内分泌]